Position in AZN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,091,684,157
New position
Shares Held
10,605,842
first reported quarter
Ownership
0.684%
of shares outstanding
% of Portfolio
0.33%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 81.71708745830011.ToString("F0")%
Shared 0.60393124808655.ToString("F0")%
None 17.67898129361334.ToString("F0")%
Derivatives in AZN
reported options exposure · as of Mar 31, 2026CallValue
$58,771,560
CallShares
298,000
PutValue
$34,888,218
PutShares
176,900
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026GOLDMAN SACHS GROUP INC holds $25,307,344,615 across 17 Drug Manufacturers - General names. AZN ranks #5 (8.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
6,340,865 | $5,832,137,397 | |
| 2 | JNJ |
Johnson & Johnson
|
18,057,047 | $4,413,864,566 | |
| 3 | ABBV |
AbbVie Inc.
|
15,145,279 | $3,293,946,727 | |
| 4 | MRK |
Merck & Co., Inc.
|
20,133,379 | $2,421,844,158 | |
| 5 | AZN |
Astrazeneca PLC
This page
|
10,605,842 | $2,091,684,157 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
11,065,214 | $1,542,158,873 | |
| 7 | AMGN |
Amgen Inc
|
4,219,989 | $1,484,803,127 | |
| 8 | PFE |
Pfizer Inc
|
47,105,556 | $1,322,724,010 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,091,684,157 | 10,605,842 | Shares | Defined | 2026-05-15 | |
| 2026-03-31 | $58,771,560 | 298,000 | Call | Defined | 2026-05-15 | |
| 2026-03-31 | $34,888,218 | 176,900 | Put | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||